Search is Powered by Google
Cancer / Oncology News

Epstein-Barr Protein Contributes To Cancer

rate icon Editor's Choice
Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry;  Genetics;  Infectious Diseases / Bacteria / Viruses
Article Date: 03 Oct 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:5 stars

5 (2 votes)

Article Opinions: 1 posts

A protein in the Epstein-Barr virus (EBV) interferes with cellular processes that would normally prevent the preservation of damaged DNA, thereby promoting cancer development, according to an article released on October 2, 2008 in the open-access journal PLoS Pathogens.

EBV is a common herpesvirus in humans. Latent infection with this virus has previously been associated with several types of cancer. One such cancer is nasopharyngeal carcinoma (NPC), which affects the upper part of the throat. In NPC, very few proteins from EBV are actively expressed, one of which is EBNA1. This product is required to maintain EVB genomes, but it has never yet been clear how this protein might contribute to cancer.

In this study, a team at the University of Toronto showed that the EBNA1 protein disrupts certain structures in the nucleus of NPC cells, called PML nuclear bodies. These complexes contain the tumor suppressor promyelocytic leukemia protein, which generally regulate DNA repair and programmed cell death. By adjusting levels of EBNA1 in each cell type, EBNA1 induced PML protein and PML body loss in NPC cells.

According to the researchers, there is "an important role for EBNA1 in the development of NPC, in which EBNA1-mediated disruption of PML nuclear bodies promotes the survival of cells with DNA damage." Other EBV associated tumors, including B-cell lymphomas and gastric carcinoma, express EBNA1, indicating that this gene might play similar roles in the development of each of these cancers. Further investigation is needed to ascertain the full role of EBNA1 in these other EBV-induced cancers.

Epstein-Barr Nuclear Antigen 1 Contributes to Nasopharyngeal Carcinoma through Disruption of PML Nuclear Bodies.
Sivachandran N, Sarkari F, Frappier L
PLoS Pathog 4(10): e1000170.
doi:10.1371/journal.ppat.1000170
Click Here For Full Length Article

Written by Anna Sophia McKenney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...